Roberto Mignone's hedge fund Bridger Management recently filed 13G's on The Princeton Review (REVU) and Medifast (MED). Due to activity on April 15th, Bridger Management has disclosed a 6.3% ownership stake in The Princeton Review (REVU) with 3,000,000 shares. Secondly, due to activity on April 16th, Roberto Mignone's hedge fund has disclosed a 5.1% ownership stake in Medifast (MED) with 787,144 shares. This position is interesting because back in March we revealed that Steven Cohen's hedge fund SAC Capital started a new position in MED. So, we now have two prominent hedge funds invested in this company.
The Princeton Review and Medifast are both brand new positions for Mignone's hedge fund as it did not own shares on December 31st when we detailed Bridger Management's portfolio. Somewhere in the last three and a half months it has assembled these stakes. In terms of other recent portfolio activity, we made note a few weeks ago of Bridger's new stake in Centene (CNC) as well.
Bridger is a $2.8 billion hedge fund focused on long/short & event driven strategies and often focus on healthcare related names. Prior to founding Bridger, Mignone co-founded Blue Ridge Capital with John Griffin in 1996. For more insight from Bridger, head to Mignone's thoughts at a previous hedge fund panel.
Taken from Google Finance,
The Princeton Review is a provider of classroom-based, print and online education products and services targeting the high school and post-secondary markets.
Medifast is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. The product lines include weight and disease management, meal replacement, and vitamins.
You can view the rest of Bridger Management's portfolio here.
Disclosure: No positions